2012 Tuberous Sclerosis Complex Clinical Trial Award Program
Page 2

With this, the funding agency requires the proposals to be submitted under this program to focus on the following areas:

a) The studies of the pathogenesis, disease severity prediction and diversity of symptoms that affects a patient's cognition, behavior, sleep, renal and pulmonary functions, along with the signs and symptoms of epilepsy and autism

b) The studies regarding the impact of TSC manifestations over the lifespan of a patient

c) The determination of novel strategies for the management and prevention of TSC manifestations including early therapeutic approaches

d) The deep comprehension of the cellular and molecular mechanisms of TSC developmental stages in mammalian and non-mammalian systems

e) Genetic, epigenetic, and non-genetic modifiers of TSC

f) The identification of biomarkers for early detection, prognosis, and prediction of TSC treatment outcomes.

To support this activities covered under this initiative, the Department of Defense is willing to administer funds in the amount of $1,600,000 per year, for a maximum project period of up to 4 years.

Assistant Professors or Lead Professors at Accredited Colleges and Universities are encouraged to submit an application under the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program.

2012 Tuberous Sclerosis Complex Clinical Trial Award Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on community grants and health grants.

Additional Resources

category - Health Grants

Strategic Alliances for Medications Development to Treat Substance Use Disorder Program
The National Institutes of Health, in cooperation with the National Institute on Drug Abuse (NIDA), has recently established the Strategic Alliances for Medications Development to Treat Substance Use Disorder Program wherein both agencies seek to support the development of substance abuse drugs by leveraging the strengths of two or more organizations toward a common goal of medications development.

---

Research to Advance Vaccine Safety Program
The Centers for Disease Control and Prevention has partnered with the National Institutes of Health and as a result, has developed the Research to Advance Vaccine Safety Program, wherein it seeks to obtain a more thorough understanding vaccine safety.

---

HIV Innovations for Improved Patient Outcomes for Priority Populations Program
The United States Agency for International Development in South Africa has recently established the HIV Innovations for Improved Patient Outcomes for Priority Populations Program wherein it intends to solicit applications coming from local organizations which are interested in heading the implementation of a five-year plan centered on the program in focus.

---

2012 Tuberous Sclerosis Complex Clinical Trial Award Program
In line with this mission, the United States Department of Defense has recently established the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program in an attempt to financially support the studies regarding the promotion innovative research focused on decreasing the clinical impact of tuberous sclerosis complex (TSC).

---